Ownership Submission
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
OMB APPROVAL
|
OMB Number:3235-0104Expires:January 31, 2005Estimated average burden hours per response...0.5
|
|
1. Name and Address of Reporting Person *
|
JANUS HENDERSON GROUP PLC
|
|
2. Date of Event Requiring Statement (Month/Day/Year)
2024-07-02
|
3. Issuer Name and Ticker or Trading Symbol
ARCA biopharma, Inc. [ABIO]
|
(Last)
|
(First)
|
(Middle)
|
201 BISHOPGATE
|
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director
|
_____ 10% Owner
|
_____ Officer (give title below)
|
_____ Other (specify below)
|
|
|
5. If Amendment, Date Original Filed(Month/Day/Year)
|
(Street)
|
LONDON
|
X0
|
EC2M 3AE
|
|
6. Individual or Join/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
|
Table I - Non-Derivative Securities Beneficially Owned
|
|
1.Title of Security
|
2. Amount of Securities Beneficially Owned
|
3. Ownership Form: Direct (D) or Indirect (I)
|
4. Nature of Indirect Beneficial Ownership
|
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
|
2. Date Exercisable and Expiration Date
|
3. Title and Amount of Securities Underlying Derivative Security
|
4. Conversion or Exercise Price of Derivative Security
|
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
|
6. Nature of Indirect Beneficial Ownership
|
Date Exercisable
|
Expriation Date
|
Title
|
Amount or Number of Shares
|
Reporting Owners
Reporting Owner Name / Address
|
Relationships
|
Director
|
10% Owner
|
Officer
|
Other
|
JANUS HENDERSON GROUP PLC
201 BISHOPGATE
LONDON, X0EC2M 3AE
|
|
X
|
|
|
Janus Henderson Biotech Innovation Master Fund Ltd
201 BISHOPGATE
LONDON, X0EC2M 3AE
|
|
X
|
|
|
Signatures
/s/ Michelle Rosenberg, CAO, General Counsel & Company Secretary
|
2024-07-12
|
**Signature of Reporting Person
|
Date
|
/s/ Janus Henderson Biotech Innovation Master Fund Ltd., By: Janus Henderson Investors US LLC, By: Peter Falconer, Assistant Secretary
|
2024-07-12
|
**Signature of Reporting Person
|
Date
|
Explanation of Responses:
(*)
|
If the form is filed by more than one reporting person, see Instruction 5(b)(v).
|
(**)
|
Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
|
(1)
|
The securities reported are beneficially owned directly by Janus Henderson Biotech Innovation Master Fund Ltd. (the "Fund"). Janus Henderson Group plc has a 100% ownership stake in Janus Henderson Investors US LLC, which serves as the investment advisor to the Fund, and may therefore be deemed a beneficial owner of the securities reported herein. Each Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein, if any.
|
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient,
See Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.